Notably, although there was not a statistically significant increase in biliary disease among GLP-1 receptor agonist users in this study, the FDA 2 added warnings and precautions about acute cholecystitis and biliary disease to the label in late 2022 based on data from placebo-controlled RCTs as well as other observational data 3
There are currently three drugs containing this active ingredient on the market, all of which are manufactured by Novo Nordisk, specifically Ozempic, Wegovy, and Rybelsus
New Drug Combinations As a workaround for the ban, some compound pharmacies are combining semaglutide or tirzepatide with additional ingredients, such as vitamin B12 or glycine, supposedly to enhance the drugs therapeutic effects
You can change, pause, and cancel anytime
Assuming it follows similar patterns, retatrutide most likely wont be recommended for people with : A history of pancreatitis Thyroid cancer or multiple endocrine neoplasia syndrome Severe kidney problems Severe liver issues Worried about side effects
Most are given by injection, but there is one pill option (Rybelsus)
